Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials

IMPORTANCE: Primary results from the Measure Up 1 and Measure Up 2 studies demonstrated upadacitinib efficacy and safety through 16 weeks in patients with atopic dermatitis. Longer-term outcomes remain unknown. OBJECTIVE: To evaluate long-term (52 weeks) efficacy and safety of upadacitinib treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Simpson, Eric L., Papp, Kim A., Blauvelt, Andrew, Chu, Chia-Yu, Hong, H. Chih-ho, Katoh, Norito, Calimlim, Brian M., Thyssen, Jacob P., Chiou, Albert S., Bissonnette, Robert, Stein Gold, Linda F., Wegzyn, Colleen, Hu, Xiaofei, Liu, Meng, Liu, John, Tenorio, Allan R., Chu, Alvina D., Guttman-Yassky, Emma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908226/
https://www.ncbi.nlm.nih.gov/pubmed/35262646
http://dx.doi.org/10.1001/jamadermatol.2022.0029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908226/
https://www.ncbi.nlm.nih.gov/pubmed/35262646
http://dx.doi.org/10.1001/jamadermatol.2022.0029

Ejemplares similares